Back to Journals Drug Design, Development and Therapy Volume 18 Clinical Pharmacokinetics of Semaglutide: A Systematic Review Received 26 March 2024 Accepted for publication 18 June 2024 Published 25 June 2024 Volume 2024:18 Pages 25552570 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Manfred Ogris Xi-Ding Yang, 1, 2 Yong-Yu Yang 1, 3 1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, Peoples Republic of China
Further analyses revealed that retatrutide led to complete resolution of excess liver fat in approximately 80% of participants with hepatic steatosis after 24 weeks, increasing to about 90%
Semaglutides action on GLP-1 receptors helps regulate appetite and reduce food intake , so patients tend to feel full sooner and eat less
CONCLUSION This study suggests that retatrutide may improve correlates of eating, such as perceived hunger and tendency to overeat, compared to placebo or dulaglutide in adults with T2D
In laboratory settings, DSIP is utilized in receptor signaling studies, neuropeptide pathway analysis, and preclinical experimental models
Individuals with a BMI of 27+ with weight-related conditions or BMI of 30+
